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Abstract. 
Malignant peritoneal mesothelioma (MPM) is rare. It is difficult to diagnose early and re-
sponds poorly to treatment. There is no optimal and effective treating consensus so far. We re-
port three patients of MPM treated at Mackay Memorial Hospital in recent 3 years. They were 
two men and one woman without asbestos exposure related to their occupations. Due to failure 
in early diagnosis of MPM, none of them survived for more than 5 months. We make a brief re-
view from the previous literature. These three cases were compared with the reviewing data in 
many aspects including the risk factor, clinical presentation, diagnostic options, and manage-
ment. Besides, some latest clinical trials are introduced in this report. 
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中文摘要 
  腹膜惡性間皮細胞瘤相當罕見。它很難早期被診斷，並且對於治療的反應也不好。
至今仍然未見有效的治療共識。我們收集到馬偕醫院這三年發現的三個病例，包含不同
職業的兩位男性與一位女性患者。由於無法早期診斷，他們存活都沒有超過五個月。我
們回顧從前發表之相關文章，在危險因子、臨床症狀、診斷策略、與相關治療這幾方面
來與我們發表的病例相比較。此外，有關最新的治療研究也在這篇文章中介紹。 
 
關鍵字: 腹膜惡性間皮細胞瘤、腹膜腫瘤、腹膜內癌轉移擴散 
 
INTRODUCTION 
Malignant mesothelioma is a malignancy arising 
from the serosal membranes of the pleura, peritoneum, 
pericardium, and tunica vaginalis testes. The pleural 
mesothelioma is the most common type followed by 
peritoneal type [1]. There is a strong relationship be-
tween asbestos exposure and the development of mes-
othelioma at any location [2]. One study pointed out 
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that the link between exposure to asbestos and perito-
neal mesothelioma is less strong than it is for pleural 
mesothelioma, particularly among women [3]. But no 
reason has been found to explain this difference. As-
bestos exposure-induced MPM generally required a 
higher cumulative dose than malignant pleural 
mesohtelioma [3]. In the United States, the overall 
prevalence is 1-2 cases per million, with an estimated 
incidence of 200-400 new cases annually [4]. In Tai-
wan Lee et al. reported a total of 423 cases of malig-
nant mesothelioma which were registered from 1979 
to 2005 [5]. Up to 91% of these patients in their study 
were diagnosed as peritoneal or pleural mesothelioma. 
The median survival of malignant mesothelioma was 
7.6 and 13.5 months for males and females, respec-
tively. The male to female ratio is 1.5:1. MPM is a 
fatal disease without specific initial clinical presenta-
tions. No serum marker or typical image criteria have 
been established to diagnose this disease early [6, 7]. 
One study for proposal of the TMN staging system for 
peritoneal mesothelioma enrolled 294 patients, of 
whom 242 patients (82.3%) were classified as stage II 
or III. The TMN staging for peritoneal mesothelioma 
has three stages with 5-year-survial rate as 87, 53, and 
29%, respectively. Therefore most cases were diag-
nosed at the advanced stage at the time of diagnosis 
[8]. We share three cases of MPM in the present 
communication.  
 
CASE REPORTS 
 
Case 1 
A 57-year-old man, a retired taxi driver, had a his-
tory of hepatitis B, diabetes mellitus, and hypertension. 
He visited the emergency department of Mackay 
Memorial Hospital because of abdominal pain and 
distention for two weeks. The chief complaints were 
poor appetite, abdominal distention and dyspnea on 
exertion for about one month. Leukocytosis (15400/ 
uL) and anemia (Hemoglobin: 8.5g/dl) were noted. 
Physical examination detected peritoneal signs (dif-
fuse rebounding pain without specific location). Then 
computed tomography of the whole abdomen revealed 
a large right liver tumor (more than 10 cm in diameter) 
and carcinomatosis (Figure 1A). Moderate amount of 
ascites was also seen. Under the impression of liver 
tumor rupture with peritonitis, he was transferred to 
the intensive care unit. A series of examinations in-
cluding of abdominal echo, cytological analysis of 
ascites, esophagogastroduodenalscopy (EGD) and 
serum tumor marker were performed in turn in order 
to discover the nature of the abdominal tumors. The 
positive findings were elevated serum, CA-125 
(297u/mL), and β2-microglobulin (9360μg/mL). Di-
agnostic laparoscopy for taking an omental specimen 
was performed. Under microscopic investigation, 
high-grade, poorly differentiated carcinoma cells were 
found (Figure 1B). The tumor cells were positive for 
some immunohistochemical staining including CK7, 
vimentin, calretinin, D2-40, thrombomodulin (Figure 
2A-2D), and negative for CEA, RCC, CK20, HepPar, 
and mucicarmine. Hepatocellular carcinoma and met-
astatic adenocarcinoma were therefore excluded. The 
pathological diagnosis was epithelioid type, pleo-
morphic subtype of MPM. This patient died of pro-
found septic shock leading to multiple organ failure 
after admission for 15 days. Due to rapid progression, 
no active treatment such as chemotherapy or radio-
therapy could be arranged for this patient. 
 
Case 2 
A 71-year-old woman, a housewife, had a history 
of diabetes mellitus. She suffered from abdominal 
pain and body weight loss of up to 5 kg within one 
month, and looked for medical advice at the hemato- 
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Figure 1. (A) Contrast computed tomography of abdomen presents with large liver tumor (red arrows) in Segments 
7, 6, and 1. Carcinomatosis, celiac trunk lymphadenopathy, and much ascites are also noted (white    
arrows). (B) Under microscopy hematoxylin and eosin stain, the omental tissue is effaced by clusters of 
high-grade epithelioid neoplastic cells with increased mitotic figures, including abnormal form 
 
 
logical outpatient service. Two liver tumors were 
found in segment 6 and 7 on abdominal sonography. 
Abdominal computed tomography demonstrated mas-
sive ascites and carcinomatosis (Figure 3). Differential 
diagnosis included hepatocellular carcinoma, meta-
static tumor from the alimentary tract or urogential 
tract. The serum CA-125 level was elevated (530.2 
u/ml). However, no tumor formation was found by 
gynecological echo. The ascites cytology revealed 
atypical reactive mesothelial cells with prominent nu-
cleoli. Due to the failure of finding out the origin of 
peritoneal tumors by noninvasive examinations, diag-
nostic laparoscopy was performed. The final diagnosis 
from biopsy specimen was epithelioid type, solid sub-
type MPM. After receiving two cycles of pemetrexed 
with cisplatin, she developed of intra-abdominal in-
fection with septic shock, which progressed to death. 
We had no time to perform further image studies to 
evaluate the response to treatment. Refractory ascites, 
however, implied that the disease was under progres-
sion. We are in lined to think that she died of progres-
sive MPM and the complication of septic shock. The 
survival period after diagnosis was only 4 months. 
 
Case 3 
A 73-year-old man, a retired labor, had a past his-
tory of coronary artery disease post-bypass graft and 
right renal stone post-extracorporeal shock wave lith-
otripsy (ESWL). Investigation was started at the 
Mackay Memorial Hospital urological outpatient 
clinic because of right flank pain and hemospermia. 
One 1.2 cm right renal stone was found. A second ses-
sion of ESWL was suggested. Three months later, he 
was still afflicted with intermittent right flank pain. 
Double colon series, pan-endoscopy, and small bowel 
series showed negative findings. Abdominal echo re-
vealed a hypo-echoic mass, suspecting a large sub-
capsular hematoma in the right liver with blood clot in 
Morrison’s pouch. The hematoma was regarded as the 
side effect of ESWL at that time. Abdominal comput-
ed tomography was arranged on account of unresolved 
symptoms including hematuria. The report confirmed 
a hematoma covering the right liver and one right re-
nal stone (Figure 4A). Two months later, he was 
transferred to the emergency department with the 
complaint of severe abdominal pain and body weight 
loss of up to 8 kg. Abdominal computed tomography 
subsequently discovered the peritoneal carcinomatosis  
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Figure 2. The tumor cells under special immunohistological stain are positive for CK7, vimentin, calretinin, and 
D2-40 
 
 
(Figure 4C,4D). A series of non-invasive examinations 
including serum tumor markers could not help in 
finding out the tumor origin. By way of diagnostic 
laparoscopy an omental specimen was obtained for 
pathological study. The diagnosis was epithelioid-type, 
tubulopapillary-subtype MPM. The gallium-67 whole 
body scan performed before the first cycle of systemic 
chemotherapy revealed rapid progression of the tumor 
into pelvic cavity compared with last abdominal 
computed tomography one month before. No further 
image examination was performed after chemotherapy. 
Therefore it was difficult to evaluate the efficacy of 
the treatment. The patient suffered from persistent 
fever and leukocytosis after the first cycle of chemo-
therapy. Finally, septic shock led the patient to his 
death. We are of the opinion that he died of progres-
sive MPM and the complication of septic shock. The 
survival period after the diagnosis of the tumors found 
by abdominal echo was 5 months, or only two months 
after final diagnosis. 
 
DISCUSSION 
According to epidemiologic data, exposure to as-
bestos is an established risk factor for developing  
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Figure 3. Contrast computed tomography of abdomen presents with prominent carcinomatosis (arrows) 
 
 
MPM [2]. The relation of relative risk to the exposure 
dose for MPM is not linear; while that for pleural 
mesothelioma is nearly linear [3]. It is presumably 
related to the dynamics controlling the distribution of 
asbestos fibers around the body which partially lodge 
into the peritoneal membrane. It is more complex than 
the absorbing mechanism of direct inhalation in pleu-
ral mesothelioma [3]. Besides asbestos, other risk 
factors including radiation and mineral fibers have 
also been reported [9,10]. With respect to the patients 
mentioned in our report, one was a taxi driver, another 
a labor, and the last a housewife. To the best of our 
acknowledge, none of them had a history of any ex-
posure to asbestos. According to the occupation risk 
factors in Sweden for MPM, bricklayers and plumbers 
had the highest risk. Farmers and self-employees had 
a relatively low risk [2]. 
There are no specific clinical presentations for di-
agnosis of MPM [4]. Most cases were asymptomatic 
until the tumors occupied most of the abdominal cav-
ity [4]. The most frequent complaint is abdominal pain 
(35%), and the second, abdominal swelling (30%) [4]. 
According to the initial clinical presentations of the 
patients in our report, their pain were often diffuse and 
nonspecific. This kind of unspecific pain often leads 
to a delay in diagnosis and till the time when these 
patients were afflicted with refractory ascites. 
There are some diagnostic strategies including la-
boratory findings and image examinations. However, 
those examinations except the histological study are 
short of high specificity and sensitivity [6,7]. Elevated 
serum levels of hyaluronan, CA-125, alpha fetoprotein, 
CEA, and mesothelin were found in some patients, but 
these levels are poorly correlated to the disease pro-
gression [6,7]. Elevated CA-125 was found in case 1 
and case 2 in our report. None of them had elevated 
serum CEA or alpha fetoprotein. Radiological exami-
nation such as computed tomography or magnetic 
resonance cannot offer adequate accuracy for differen-
tial diagnosis [7]. Combined image guiding biopsy 
and immunohistochemical staining can help in diag-
nosing MPM precisely [11]. Cytologic analysis of 
ascites has its limitations in differential diagnosis of 
malignant or benign reactive peritoneal mesothelioma 
because it lacks the evidence of stromal invasion to 
peritoneum [11,12]. In the beginning, the contrast 
computed tomography failed to detect a peritoneal 
lesion in case 3 until the disease progressed to perito-
neal carcinomatosis. 
It is difficult to distinguish MPM from some peri-
toneal tumors which mimic MPM in the clinical and 
image patterns by the histological appearance. Those  
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Figure 4. (A,B) Pictures of first contrast abdominal computer tomography. In Figure 4A, the hypodense area (ar-
row) covering right liver surface is thought to be a hematoma. However, omental thickening (arrow) is 
also noted in the right lower abdominal quadrant in Figure 4B. (C,D) These are pictures of subsequent 
liver dynamic computed tomography (arterial phase) 2 months afterward. Obvious abdominal carcino-
matosis is found (arrow) 
 
 
tumors are: sarcoma, melanoma, primary papillary 
serous carcinoma of the peritoneum, serous ovarian 
carcinomas, colorectal adenocarcinoma diffusely in-
volving the peritoneum, and borderline serous tumors 
[4]. A panel with immunohistochemical markers has 
been suggested for diagnostic aid [13]. Most mesothe-
liomas stain positively for antimesothelial cell anti-
body-1, D2-40, calretinin, cytokeratins5/6, Wilms tu-
mor-1, thrombomodulin, and mesothelin which are 
absent in those serous carcinoma mentioned above. 
Cytokeratin statins are absent in sarcoma and mela-
noma. Mesotheliomas usually stain negative for other 
adenocarcinoma markers, including carcinoembryonic 
antigen (CEA), thyroid transcription factor-1, LeuM1, 
Ber-Ep4, B72.3, Bg8, and MOC-31. 
Mesotheliomas have three basic histologic forms: 
epithelioid (the most frequent), sarcomatoid (least 
frequent), and mixed (biphasic). In most cases, all 
three type features will be encountered in a single tu-
mor [13]. The morphological category is based on the 
2004 World Health Organization (WHO) criteria (less 
than 10% sarcomatoid component defined as epitheli-
oid type; otherwise defined as biphasic type) [14]. The 
pure sarcomatoid type peritoneal mesothelioma is very 
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rare. In general, the epithelioid type has the best 
prognosis, followed by the biphasic type [14]. Ac-
cording to the 2004 WHO classification, the malignant 
epithelioid mesothelioma have five histological sub-
types, that is, trabecular, tubulopapillary, micropapil-
lary, solid, and pleomorphic [14]. There is no pub-
lished paper in the literature discussing the prognostic 
difference of each epithelioid subtype in malignant 
peritoneal mesothelioma. One research, however, re-
ported this difference with malignant pleural mesothe-
lioma [14]. In that study, the trabecular and tubulopa-
pillary subtypes had a longer overall survival time 
than the micropapillary and pleomorphic subtypes. 
The pleomorphic subtype, in particularly, was an in-
dependent predictor for worse overall survival in the 
multivariate analysis setting. The pleomorphic subtype 
showed no significant difference in overall survival 
compared with biphasic (p=0.96) and sarcomatoid type 
(p=0.15). The authors defined the solid and micro-
papillary as high-grade subtype in epithelioid mesothe-
lioma. With regard to the pleomorphic subtype which 
had aggressive clinical and biologic behavior such as 
prominent lymphatic, vascular invasion, and rapid re-
currence, the authors proposed that it was best regard-
ed as a sarcomatoid pattern rather than an epithelioid 
one. There were some histological features belonging 
to epithelioid mesothelioma, namely, microcystic, clear 
cell, deciduoid, and small cell types. That study did not 
demonstrate any association of those histological fea-
tures with prognosis. Multicytic peritoneal mesotheli-
oma and well-differentiatedpapillary mesothelioma are 
two rare subgroups which are nearly always encoun-
tered in peritoneal mesothelioma of females. They are 
variants of epithelioid mesothelioma and have excel-
lent prognosis [13]. 
Due to rarity and lack of prospective large scale 
clinical trials, there is still no consensus for optimal 
treatment so far. Localized MPM can be resected by 
surgical intervention. However, the diffuse-type of 
invasive mesothelioma was managed with chemo-
therapy and even radiotherapy after palliative surgery 
in the past [9]. The median survival period was uni-
formly less than one year, and long-term survival was 
uncommon [15]. The median survival for untreated 
patients was approximately 6 months [15]. Over the 
past 5 years, experiences in cytoreductive surgery 
(CRS) and hyperthemic intraperitoneal chemotherapy 
(HIPC) were accumulated gradually. Markedly im-
proved outcomes including the survival rate have been 
reported. Some papers reported their phase II and ob-
servation experiences with CRS and HIPC in the US 
and Europe reaching the satisfied outcome with an 
overall fiver-year survival rates ranging from 29% to 
57%, and median survival time of up to 70 months [16, 
17]. The advantages of CRS combined with HIPC 
over the conventional systemic chemotherapy are that 
they remove macroscopic tumors, decreasing tumor 
burden [16,17]. Heated and direct-contact chemother-
apy drugs provide higher concentration and penetra-
tion into mesentery nodules [17, 18]. However not all 
patients are candidates for CRS and HIPC; patients 
with poor performance and extra-peritoneal metastasis 
are not suitable for such treatment [17]. Moreover the 
skill of the surgeon plays an important role in com-
pleteness of cytoreduction surgery [19]. Based on the 
best knowledge and a report in the literature, a re-
search by Pubmed et al, there is no published report 
from Taiwan on the application of HIPC and cy-
toredutive surgery in MPM. In our report, these three 
patients did not undergo cytoreductive surgery and 
HIPC. This was due either to advanced disease with 
liver metastasis and our lacking of experience. This 
approach may be adopted in the future with gathering 
more evidence and increased experience in cytoreduc-
tion surgery. 
In 2004, pemetrexed was approved worldwide to 
be used in combination with cisplatin for the treatment 
of malignant pleural mesothelioma in patients whose 
disease was not resectable [20]. However, up to now 
no chemotherapeutic agent, either alone or in combi-
nation, has demonstrated a consistent survival ad-
vantage in peritoneal mesothelioma. Currently, there is 
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no approved treatment for peritoneal mesothelioma 
[20]. Many researches on evaluating the efficacy pro-
file when peritoneal mesothelioma patients were 
treated with pemetrexed with or without a platinum 
agent demonstrate that pemetrexed or cisplatin alone 
is inferior to pemetrexed combined with cisplatin or 
carboplatin in the response rate [20]. One study re-
ported this difference among these regimens in the 
response rate [20] (pemetrexed, pemetrexed with cis-
platin, and pemetrexed with carboplatin): 12.5%, 
20.0%, and 24.1%, respectively. Pemetrexed com-
bined with cisplatin is still thought to be more effi-
cient in treating MPM.  
Recently molecularly targeted therapy agents have 
been introduced to treat advanced malignant mesothe-
lioma (including pleural type). Tremelimumab in a 
small single arm, phase II study reported positive 
treating outcome [21]. Tremelimumab is a monoclonal 
antibody of cytotoxic T-lymphocyte antigen 4 
(CTLA4), which is a powerful negative regulator of T 
cell activation. By means of blockage of CTLA4, the 
activated cytotoxic T lymphocyte can eliminate the 
tumor cells more efficiently. This study enrolled only 
29 participants. Though none-attained a complete re-
sponse, two patients (7%) had a durable partial re-
sponse (one lasting 6 months and the other lasting 18 
months). However nine patients (31%) had a median 
progression-free survival of only 6.2 months. The au-
thor recognized that tremelimumab seemed to have 
encouraging clinical activity in previously treated pa-
tients with advanced malignant mesothelioma. Other 
experimental approaches with immunotherapeutic 
agents including bevacizumab, thalidomide, sorafenib, 
sunitinib, imatinib, vatalanib, cediranib, and vorinostat 
[22-29] have been reported, but no established role 
has yet been found in the treatment of mesothelioma.  
In conclusion, MPM is a rare, highly lethal, and 
rapidly progressive malignancy. There is no consensus 
for established treatment so far. Further researches for 
MPM are ongoing and we hope that they will offer us 
a better, feasible treatment in the future. 
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